Mountain Valley MD Inc (PK) (MVMDF)

Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157May 29, 2026 8:30 AM
Business Wire Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to report on the advancement of its patented Quicksome™ sublingual delivery platform as part of the Company’s strategy to position Quicksome™ as a differentiated delivery solution within the evolving compounded peptide marketplace across North and South America. Over the past six months, the Company has expanded its internal formulation capabilities following investments in laboratory equipment and capabilities to support direct work with sensitive molecules, including peptides and bioactive compounds requiring controlled environment handling and stability-focused formulation work. Through this program, the Company has completed initial Quicksome™ sublingual formulation work across several peptides currently drawing noteworthy attention within the compounded pharmacy channel, including BPC-157, GHK-Cu, KPV, SNAP-8, and retatrutide. Dosing finalization is being conducted across several of these programs in preparation for anticipated compounded pharmacy commercialization opportunities. The Company’s current programs are focused on evaluating sublingual delivery applicability, formulation stability characteristics, and commercial potential within the compounded pharmacy network. The Company is not developing proprietary peptide drugs and does not hold ownership rights to any of the underlying peptide molecules referenced in this release. “We believe the peptide category is entering one of the most important growth periods in its history,” stated Dennis Hancock, President and CEO of MVMD. “Our focus is entirely on Quicksome™ as a differentiated delivery platform that we believe has the potential to move important molecules from needle-based administration and refrigerated logistics toward a more accessible sublingual format. Six months ago we began the formulation work to demonstrate that. Today we are reporting that the platform is applicable across multiple peptides of commercial significance. We believe we are well positioned to serve as an important delivery option for broader consumer adoption as this market evolves.” QUICKSOME™ SUBLINGUAL DELIVERY PLATFORM A fundamental challenge in peptide administration is bioavailability. Peptide chains are highly susceptible to degradation by the harsh acidic environment of the stomach and the proteolytic enzymes of the gastrointestinal tract, which break down peptide bonds before the active molecule can reach systemic circulation. The result is that conventional oral peptide formulations typically achieve negligible systemic bioavailability, making injection the dominant delivery method across most clinically active peptides in use today. Sublingual delivery bypasses the gastrointestinal tract entirely, allowing molecules to be absorbed directly through the highly vascularized tissue beneath the tongue and enter systemic circulation without first-pass degradation. Quicksome™ is the Company’s patented sublingual rapid-dissolve delivery technology. Active molecules are formulated into a tablet that dissolves under the tongue, designed to provide systemic delivery without injection. For peptides currently requiring refrigeration and needle-based administration, the Company believes this format may offer several potential advantages: needle-free administration and improved patient convenience potential elimination or reduction of refrigerated handling requirements expanded distribution flexibility and commercial accessibility improved regimen compliance for needle-adverse patients The Company’s cold chain credentialing is grounded in validation work conducted under a formal two-year collaborative research agreement with the FDA (U.S. Food and Drug Administration), announced in June 2021. In the Company’s initial cold chain evaluation, Quicksome™ technology achieved 100% preservation and stability of IPV serotype two of a Trivalent Inactivated Poliovirus Vaccine (tIPV) after five days of exposure to 40 degrees Celsius, meeting the World Health Organization’s requirements across all three defined vaccine cold chain management categories, including the Controlled Temperature Chain standard which requires tolerance of 40 degrees Celsius for a minimum of three days. IPV serotypes one and three achieved 50% preservation in the same evaluation. The Company believes these results demonstrate the platform’s capability to preserve and stabilize heat-sensitive biological molecules outside of a refrigerated environment — a characteristic it considers directly beneficial to the compounded peptide category.1 THE COMPOUNDED PEPTIDE MARKET Peptides are naturally occurring chains of amino acids that function as biological signaling molecules involved in tissue repair, hormonal regulation, metabolic function, immune response, and other physiological processes. Peptide therapeutics have been used clinically for decades across oncology, endocrinology, metabolic disease, and regenerative medicine, with the FDA having authorized approximately 100 peptide-based medicines to date.2 The global peptide therapeutics market was valued at approximately USD $141 billion in 2025 and is projected to reach approximately USD $295 billion by 2033, growing at an approximately 8.7% compound annual growth rate.3 A recent development within the category has been with regard to the GLP-1 receptor agonist class. Therapies anchored by semaglutide and tirzepatide generated combined global reported revenues of approximately USD $46 billion in 2024. The next-generation GLP-3 class, anchored by retatrutide — Eli Lilly’s triple agonist currently in Phase III clinical trials — is projected by leading industry analysts to generate revenues in the range of USD $15 billion to USD $30 billion by 2031 for Lilly alone. The Company does not own, develop, or hold any rights to GLP-class molecules. The Company’s work in this area is limited to evaluating the applicability of its Quicksome™ delivery platform to such molecules within the compounded pharmacy channel.4 The Company’s formulation and commercialization activities are not dependent solely on the potential expansion of categories currently under regulatory review. Several GLP-class therapies and other peptide molecules are already commercially established within approved pharmaceutical and compounded pharmacy channels. The Company notes, however, that the United States regulatory framework surrounding compounded peptides continues to evolve in a direction that may materially expand the addressable market for differentiated delivery technologies. On February 27, 2026, United States Secretary of Health and Human Services Robert F. Kennedy Jr. publicly stated that approximately 14 peptides currently classified on the FDA’s Category 2 Bulk Drug Substances List — a designation that has restricted their use by compounding pharmacies — are expected to be considered for potential return to Category 1 status, which would permit licensed compounding pharmacies to prepare them under physician prescription. On April 16, 2026, the FDA confirmed a Pharmacy Compounding Advisory Committee (“PCAC”) meeting scheduled for July 23 and 24, 2026, at which seven peptides will be reviewed for potential inclusion on the 503A Bulk Drug Substances List: BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, and Epitalon. A second meeting anticipated before February 2027 will review five additional peptides including GHK-Cu, Melanotan II, Cathelicidin, Dihexa acetate, and PEG-MGF. The Company notes that a positive Committee recommendation initiates a formal rulemaking process and that the timing of any reclassification remains subject to that process. “The regulatory environment appears to be moving toward a broader re-evaluation of compounded peptides, and we believe that creates a potentially important opening for differentiated delivery technologies,” commented Mr. Hancock. “BPC-157 is on the FDA’s formal review list. Retatrutide is one of the most closely watched pharmaceutical developments of this decade. Our role is not to own or develop these molecules. Our role is to be the platform that enables simpler, more accessible delivery of them and our team has spent the past six months building exactly that capability.” COMMERCIALIZATION STRATEGY MVMD’s peptide-related initiatives are being advanced within the Company’s broader Quicksome™ commercialization framework, which is focused on compound pharmacy partnerships, formulation licensing arrangements, and regional commercialization structures across North and South America. The Company continues to advance business development discussions related to Quicksome™ applications across multiple human health categories, including peptide-based therapies, weight management, hormonal health, recovery, anti-aging, and other bioactive molecule applications. Current activities within the Company’s commercialization framework include ongoing formulation refinement, dosing optimization work, stability assessment, compound pharmacy engagement discussions, and evaluation of regional commercialization structures intended to support future Quicksome™ product deployment across North and South America. The Company’s current strategy is focused on establishing Quicksome™ as a platform technology that may be licensed, integrated, or commercialized through compound pharmacy, telehealth, wellness, and broader bioactive molecule distribution relationships, rather than pursuing traditional pharmaceutical drug development pathways. MVMD expects its next phase of work to include continued formulation advancement, expanded business development discussions, and evaluation of potential pilot commercialization opportunities involving select Quicksome™ peptide applications where legally permissible and commercially appropriate. “Quicksome™ is a platform technology, not a single-product opportunity,” said Mr. Hancock. “The commercial case is straightforward: if we can take molecules that currently require refrigeration and injection and reformulate them into a sublingual tablet that is stable at room temperature and can be taken without a needle, we change the distribution economics and the patient experience for that molecule entirely. Our strategy is not dependent on any single regulatory outcome as many of the largest peptide categories already exist within established compounded markets today. What the current regulatory review process potentially does is expand that universe materially. We believe we are building infrastructure for a category that is growing rapidly.” ABOUT MOUNTAIN VALLEY MD HOLDINGS INC. Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations: patented Quicksome™ oral formulation and delivery technologies, patented Quicksol™ solubility formulation technology licensed product reseller of Agrarius™, a novel agricultural plant signaling technology Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage. MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy. MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally. MVMD’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change. For more Company information and contact details, visit www.MVMD.com. REFERENCE SOURCES 1 World Health Organization, “The Controlled Temperature Chain,” 2016; Mountain Valley MD Holdings Inc., news release dated July 7, 2021 (MVMD initial cold chain evaluation results under formal FDA collaborative research agreement).
2 U.S. Food and Drug Administration; see also Muttenthaler M. et al., “Trends in peptide drug discovery,” Nature Reviews Drug Discovery, 2021, 20(4):309–325.
3 Grand View Research, “Peptide Therapeutics Market Size | Industry Report, 2033,” grandviewresearch.com/industry-analysis/peptide-therapeutics-market, accessed May 2026.
4 Novo Nordisk Annual Report 2024 (semaglutide products: DKK 201.84 billion, approx. USD $29.3 billion); Eli Lilly 2024 Annual Report (tirzepatide: USD $16.46 billion). Combined approx. USD $45.8 billion. GLP-3 projections: GlobalData, “Obesity in Major Markets — Forecast to 2031” (USD $15.6 billion for retatrutide by 2031); Clarivate, “Drugs to Watch 2026” (USD $30 billion by 2031). These are third-party analyst projections. The Company makes no representation as to their accuracy. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Forward-looking information in this news release includes, among other things, statements regarding the Company’s peptide delivery platform strategy and anticipated commercial opportunities therefrom; the anticipated progression of the United States regulatory review process for compounded peptides, including the outcome of the Pharmacy Compounding Advisory Committee’s July 2026 meeting and any subsequent rulemaking; the potential commercial applications of the Company’s Quicksome™ technology in the compounded peptide and GLP-class peptide categories; the Company’s ongoing formulation and delivery programs including work relating to BPC-157, GHK-Cu, KPV, SNAP-8, retatrutide, and other molecules; and the anticipated size and growth of the global peptide therapeutics market. The Company’s actual results could differ materially from those anticipated in such forward-looking information as a result of regulatory decisions, the outcome of the FDA’s formal review process and any rulemaking regarding compounded peptides, competitive factors in the industries in which the Company operates, the Company’s ability to successfully complete formulation programs and advance them into commercial relationships, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. Neither the CSE nor OTC has reviewed or approved the contents of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260529480330/en/ For further information: Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Investor Relations @BenK-9755
Email: info@mvmd.com
www.MVMD.com Original: Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

CORRECTING and REPLACING Mountain Valley MD Announces Appointment of Advisors and Stock Option GrantsApril 17, 2026 10:12 PM
Business Wire
Please replace the release with the following corrected version due to multiple revisions.


The updated release reads:


MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTS


Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) announces that it is issuing this amended and updated news release to correct inadvertent errors in the biographical information of certain advisors previously announced in its news release issued earlier today. All other information in the original news release remains unchanged.


APPOINTMENT OF ADVISORS


The Company has appointed the individuals listed below as advisors to provide strategic advisory services on customary commercial terms, with any compensation subject to applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”).


“I am very pleased to welcome this group of advisors to MVMD,” commented Dennis Hancock, President and CEO of MVMD. “Their collective experience across human health, agriculture, formulation science, and capital markets aligns directly with our strategic priorities. As we continue to advance technologies in areas such as peptides and repurposed therapeutics, including emerging commercialization opportunities, we believe this group significantly strengthens our ability to execute and build long-term value.”


Aubrey Marcus

Founder of Onnit, which he scaled to a nine-figure exit, and a recognized leader in human performance and wellness. Aubrey is a New York Times bestselling author and host of a widely followed podcast, with a demonstrated ability to translate emerging health technologies into broad consumer adoption. His experience in branding, storytelling, and distribution, combined with an extensive network across entrepreneurs, athletes, and investors, supports strategic partnerships, capital alignment, and market positioning.


Bode Miller

Olympic gold medalist and one of the most decorated alpine skiers in history, known for precision, resilience, and elite performance. Bode has expanded into entrepreneurship, agriculture, and wellness, with direct involvement in farming and land-based systems. He brings a practical perspective on performance optimization and agricultural innovation, along with relationships across sports, investment, and regenerative food systems.


Shawn Wells

Widely regarded as a leading formulator in the nutraceutical industry, Shawn Wells is a nutritional biochemist behind numerous commercially successful ingredients and products. He holds multiple patents across ingredients and formulations and has worked with many global supplement brands. His expertise in bioavailability, ingredient innovation, peptide science, and regulatory strategy supports product development and scalability, with a focus on optimizing stability, delivery systems, and real-world efficacy.


Emily Kaplan

Emily Kaplan is an entrepreneur, operator and strategic communications expert operating at the intersection of health innovation, science literacy, and business growth. As CEO and Co-founder of MetFix, a national network of 150+ brick-and-mortar affiliate locations deploying evidence-informed metabolic health protocols and the Broken Science Initiative, she has built a two-pronged platform addressing the root cause of the chronic disease epidemic. As founder of The Kleio Group, she advises politicians, celebrities, and CEOs through crisis, launch, and strategic pivots. A 2x HarperCollins business author and former producer for ABC News' 20/20, Primetime, and Good Morning America, she has been featured in The Wall Street Journal and The New York Times. Emily brings two decades of experience translating complex science and high-stakes narratives into clear, actionable strategy. She is a recognized voice in performance health and alternative health ecosystems, known for identifying early-stage breakthroughs and the influence to move them forward.


Janet Zand

Dr. Janet Zand is a pioneer in integrative medicine with decades of experience combining conventional and complementary therapies. She has been actively involved in exploring and advancing repurposed therapeutics, within broader treatment frameworks. She is a co-founder and formulator for Zand Formulas, Humann and Pure BioHealth. She was the lead researcher on the first published, researched nitric oxide nutraceutical which now has had over 1.5 million doses. Dr. Zand brings seasoned clinical expertise, regulatory awareness, and a patient-centered approach, strengthening the company’s credibility across both medical and consumer health landscapes.


Mark Gelnaw

Mr. Gelnaw is a senior financial executive with more than 35 years of experience in financial management, corporate strategy, and business leadership. He has served as Chief Operating Officer of Deutsche Bank and Chief Operating and Financial Officer at Lehman Brothers, and held senior roles at Salomon Brothers and Arthur Andersen. He also acted as CEO and CFO of Cynvec LLC, a cancer research company partnered with NYU. Mr. Gelnaw sits on numerous business advisory boards for both profit and non-profit organizations and is the founder of Breakwater Ventures, which manages investments across multiple sectors including healthcare, technology, and financial services.


Alex Wolfe

Alex Wolfe is a founder, operator, and brand builder with over 12 years of experience in regulated and emerging markets, including psychedelics and nutraceuticals. As the founder of Eons, a global health and wellness company focused on functional mushroom-based products, he works to combine adaptogenic compounds with advanced biotechnology platforms, including MVMD’s Quicksome™ technology, to support the development of differentiated consumer health products. He brings experience in business development, commercialization, and market positioning, with a focus on scaling innovative technologies in high-growth categories.


Dan Engle

Dr. Dan Engle is a board-certified psychiatrist with expertise in integrative mental health and emerging therapeutic approaches, including psychedelic-assisted therapy. He has extensive experience working with trauma, veterans, and high-performance individuals, bridging conventional psychiatry with evolving treatment modalities. Dr. Engle contributes clinical perspective, ethical oversight, and domain expertise in neurological and mental health innovation.


Domingos S. S. Junior

Domingos S. S. Junior is the founder and lead investor at DSJ Capital, a U.S.-based private equity firm. He brings more than two decades of experience across pharmaceutical, cosmetic, food, and medical device industries, with deep expertise in regulatory affairs, quality systems, and manufacturing operations. Domingos previously served for over 20 years at ANVISA as a Senior Regulatory Affairs Specialist, with experience in GMP inspections, regulatory policy, and international coordination, including participation in ICH forums. His background supports regulatory strategy, manufacturing scale-up, and international market development.


Luis Felipe Scarpa Street

Luis Felipe Scarpa Street is an investor and entrepreneur with over 25 years of experience across financial services, biotechnology, and industrial ventures. He co-founded and managed a Brazilian hedge fund later acquired by Bradesco and has held executive leadership roles in marketing and business development. He is currently Chief Business Development Officer at Tecbio and co-founder of Biogrowth do Brasil. His experience spans capital markets, biotechnology commercialization, and industrial applications, supporting business capitalization and strategic growth initiatives.


STOCK OPTION GRANT


The Company also announces that, pursuant to the Company’s Stock Option Plan, an aggregate of 15,100,000 incentive stock options have been granted to certain directors, officers, and consultants/advisors of the Company at an exercise price of $0.06 per share. The options are exercisable for a period of five years, with 20% vesting on the date of grant, 30% vesting on the 6-month anniversary following the date of grant and the remaining 50% vesting on the 12-month anniversary following the date of grant. Any securities issued upon exercise of the options will be subject to any applicable resale restrictions under CSE policies and securities laws.


“The granting of stock options is an important component of our approach to aligning our team and advisors with long-term shareholder value,” commented Dennis Hancock, President and CEO of MVMD. “This structure allows us to preserve cash while ensuring that those contributing to the Company’s progress are directly incentivized alongside our shareholders as we continue to execute on our strategic priorities.”


ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.

Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:



patented Quicksome™ oral formulation and delivery technologies,



patented Quicksol™ solubility formulation technology



licensed product reseller of Agrarius™, a novel agricultural plant signaling technology



Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.


MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.


MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.


MVMD’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.


For more Company information and contact details, visit www.MVMD.com.


SOURCE: Mountain Valley MD Holdings Inc.


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION


Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.


Forward-looking information in this news release includes, among other things, statements regarding the Company’s future plans, operations and performance, including the expected contributions of the Advisors and the Company’s ability to execute on its strategic priorities. Statements regarding the expected use of proceeds are based on management’s current intentions and are subject to change depending on, among other things, future operating requirements and the availability of alternative sources of financing. The Company’s actual results could differ materially from those anticipated in such forward-looking information as a result of, among other things, general economic, market and business conditions, and other factors, many of which are beyond the control of the Company.


The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.


Neither the CSE nor OTC has reviewed or approved the contents of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417773204/en/
For further information:

Dennis Hancock

President and Chief Executive Officer

Mountain Valley MD Holdings Inc.

Investor Relations @BenK-9755

Email: info@mvmd.com

www.MVMD.com


Original: CORRECTING and REPLACING Mountain Valley MD Announces Appointment of Advisors and Stock Option Grants

Mountain Valley MD Announces Appointment of Advisors and Stock Option GrantsApril 17, 2026 8:15 AM
Business Wire
Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to announce the appointment of multiple advisors to the Company as well as the grant of stock options to certain directors, officers, and consultants/advisors of the Company.


APPOINTMENT OF ADVISORS


The Company has appointed the individuals listed below as advisors to provide strategic advisory services on customary commercial terms, with any compensation subject to applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”).


“I am very pleased to welcome this group of advisors to MVMD,” commented Dennis Hancock, President and CEO of MVMD. “Their collective experience across human health, agriculture, formulation science, and capital markets aligns directly with our strategic priorities. As we continue to advance technologies in areas such as peptides and repurposed therapeutics, including emerging commercialization opportunities, we believe this group significantly strengthens our ability to execute and build long-term value.”


Aubrey Marcus

Founder of Onnit, which he scaled to a nine-figure exit, and a recognized leader in human performance and wellness. Aubrey is a New York Times bestselling author and host of a widely followed podcast, with a demonstrated ability to translate emerging health technologies into broad consumer adoption. His experience in branding, storytelling, and distribution, combined with an extensive network across entrepreneurs, athletes, and investors, supports strategic partnerships, capital alignment, and market positioning.


Bode Miller

Olympic gold medalist and one of the most decorated alpine skiers in history, known for precision, resilience, and elite performance. Bode has expanded into entrepreneurship, agriculture, and wellness, with direct involvement in farming and land-based systems. He brings a practical perspective on performance optimization and agricultural innovation, along with relationships across sports, investment, and regenerative food systems.


Shawn Wells

Widely regarded as a leading formulator in the nutraceutical industry, Shawn Wells is a nutritional biochemist behind numerous commercially successful ingredients and products. He holds multiple patents across ingredients and formulations and has worked with many global supplement brands. His expertise in bioavailability, ingredient innovation, peptide science, and regulatory strategy supports product development and scalability, with a focus on optimizing stability, delivery systems, and real-world efficacy.


Emily Kaplan

Emily Kaplan is an entrepreneur, operator, and strategic communications expert focused on health innovation, science communication, and business growth. As CEO and Co-founder of MetFix, a national network of over 150 locations delivering evidence-informed metabolic health protocols, and the Broken Science Initiative, she has built platforms addressing chronic disease through emerging therapeutics, including peptides and repurposed compounds such as ivermectin. As founder of The Kleio Group, she advises political leaders, executives, and public figures on strategy and communications. A two-time HarperCollins business author and former ABC News producer, she brings extensive experience translating complex science into clear, actionable strategy.


Janet Zand

Dr. Janet Zand is a pioneer in integrative medicine with decades of experience combining conventional and complementary therapies. She has been actively involved in advancing repurposed therapeutics, including ivermectin, within broader treatment frameworks. She is a co-founder and formulator behind multiple nutraceutical and health-focused product lines and contributed to early research in nitric oxide-based supplementation. Dr. Zand brings clinical expertise, formulation and R&D experience, regulatory awareness, and a patient-centered perspective, supporting the Company’s positioning across both medical and consumer health markets.


Mark Gelnaw

Mr. Gelnaw is a senior financial executive with more than 35 years of experience in financial management, corporate strategy, and business leadership. He has served as Chief Operating Officer of Deutsche Bank and Chief Operating and Financial Officer at Lehman Brothers, and held senior roles at Salomon Brothers and Arthur Andersen. He also acted as CEO and CFO of Cynvec LLC, a cancer research company partnered with NYU. Mr. Gelnaw is the founder of Breakwater Ventures, which manages investments across multiple sectors including healthcare, technology, and financial services.


Alex Wolfe

Alex Wolfe is a founder, operator, and brand builder with over 12 years of experience in regulated and emerging markets, including psychedelics and nutraceuticals. As the founder of Eons, a global health and wellness company focused on functional mushroom-based products, he works to combine adaptogenic compounds with advanced biotechnology platforms, including MVMD’s Quicksome™ technology, to support the development of differentiated consumer health products. He brings experience in business development, commercialization, and market positioning, with a focus on scaling innovative technologies in high-growth categories.


Dan Engle

Dr. Dan Engle is a board-certified psychiatrist with expertise in integrative mental health and emerging therapeutic approaches, including psychedelic-assisted therapy. He has extensive experience working with trauma, veterans, and high-performance individuals, bridging conventional psychiatry with evolving treatment modalities. Dr. Engle contributes clinical perspective, ethical oversight, and domain expertise in neurological and mental health innovation.


Domingos S. S. Junior

Domingos S. S. Junior is the founder and lead investor at DSJ Capital, a U.S.-based private equity firm. He brings more than two decades of experience across pharmaceutical, cosmetic, food, and medical device industries, with deep expertise in regulatory affairs, quality systems, and manufacturing operations. Domingos previously served for over 20 years at ANVISA as a Senior Regulatory Affairs Specialist, with experience in GMP inspections, regulatory policy, and international coordination, including participation in ICH forums. His background supports regulatory strategy, manufacturing scale-up, and international market development


Luis Felipe Scarpa Street

Luis Felipe Scarpa Street is an investor and entrepreneur with over 25 years of experience across financial services, biotechnology, and industrial ventures. He co-founded and managed a Brazilian hedge fund later acquired by Bradesco and has held executive leadership roles in marketing and business development. He is currently Chief Business Development Officer at Tecbio and co-founder of Biogrowth do Brasil. His experience spans capital markets, biotechnology commercialization, and industrial applications, supporting business capitalization and strategic growth initiatives.


STOCK OPTION GRANT


The Company also announces that, pursuant to the Company’s Stock Option Plan, an aggregate 15,100,000 incentive stock options have been granted to certain directors, officers, and consultants/advisors of the Company at an exercise price of $0.06 per share. The options are exercisable for a period of five years, with 20% vesting on the date of grant, 30% vesting on the 6-month anniversary following the date of grant and the remaining 50% vesting on the 12-month anniversary following the date of grant. Any securities issued upon exercise of the options will be subject to any applicable resale restrictions under CSE policies and securities laws.


“The granting of stock options is an important component of our approach to aligning our team and advisors with long-term shareholder value,” commented Dennis Hancock, President and CEO of MVMD. “This structure allows us to preserve cash while ensuring that those contributing to the Company’s progress are directly incentivized alongside our shareholders as we continue to execute on our strategic priorities.”


ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.

Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:



patented Quicksome™ oral formulation and delivery technologies,



patented Quicksol™ solubility formulation technology



licensed product reseller of Agrarius™, a novel agricultural plant signaling technology



Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.


MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.


MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.


MVMD’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.


For more Company information and contact details, visit www.MVMD.com.


SOURCE: Mountain Valley MD Holdings Inc.


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION


Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.


Forward-looking information in this news release includes, among other things, statements regarding the Company’s future plans, operations and performance, including the expected contributions of the Advisors and the Company’s ability to execute on its strategic priorities. Statements regarding the expected use of proceeds are based on management’s current intentions and are subject to change depending on, among other things, future operating requirements and the availability of alternative sources of financing. The Company’s actual results could differ materially from those anticipated in such forward-looking information as a result of, among other things, general economic, market and business conditions, and other factors, many of which are beyond the control of the Company.


The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.


Neither the CSE nor OTC has reviewed or approved the contents of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417773204/en/
For further information:

Dennis Hancock

President and Chief Executive Officer

Mountain Valley MD Holdings Inc.

Investor Relations @BenK-9755

Email: info@mvmd.com

www.MVMD.com


Original: Mountain Valley MD Announces Appointment of Advisors and Stock Option Grants

Shorts have found so many ways to cheat the longs and the markets.  I appreciate the effort the buying frenzy, hope it’s based on success and not the greater fool theory.  ,, as shorts cheat like hell already owns their souls..

Smitty, you still in Spectra7?

Hopefully they are working towards good news while they burn cash. This used to be a gold mine for me....literally

Word of the year for mvmd is DOWN. Its like a re-start because Nothing is happening and anything in past almost doesnt matter because its not moving. I dont mind companies that dont do PR often however this one has gotten bad.

The Update was a reprint. Showed he doesnt care what he says to shareholders or knows he doesnt have many shareholders.
Everyone should have been expecting news about India, but he just talked right past it which usually means things arent going well.
Did license deal in Nov with Bloom brands and No Follow Up? Wow

Trading ideas on this have switched.
Overall this is dead money until there is volume on canadian exchange which will mean there is actually something happening. If so, this is pretty low so it should move up quickly.
Good thing is he doesnt have alot of expenses, running lean and they have Cash. Without the Cash I would not watch this one.

Key will be volume before the news, so just watching

Waddup?

Would you consider this a run up? No News Yet.
I am guessing some people are loading up for expected India drug announcements, volume has been good on canadian exchange
Quiet on US side

Lots of info coming out to show that IV is effective, the DOD emails pretty much make fauci a lying bureaucrat who has been compromised, and our govt health shut it down, so much for govt trying to help their people

If Mountain Valley is successful with IV in India they can go alot of places quickly with this, just need that Approval

Yes

Maybe alot of that selling is done because the volume the past week has been on the buy side.
In past they would have 2-3 days of buy to move price then start the selling, Today over million shares traded in first hour and just over 70% are buys, that looks like a positive sign.

They have been working on and finished project in India, they set up a company to make product over there, just waiting for official word from India Health that its a go. My opinion is Problem is big pharma doesnt want any progress on anything associated with i-vermectin so politics and big pharme money are holding up public release.

So many covid cures and early treatment are being slow walked by authorities so big pharma can sell experimental mrna vax drug, really sad how compromised our health system has become

Kuious if this moving based on what SCOTUS Thomas said today in the Mandates case.

Justice Thomas - I’m curious… Is a vaccine the only way to treat COVID?

Waiting on ivermectin manubandcanimal clijibcal pass in
Indinesia? Or Moldavia or Montenegro or Albania.. somebody has made a lot of money off 300,000,000 shares and almost none of it went to the company..that I can see…

MVMDF, This Canadian Scam is a typical Pump and Dump!

Hope you're right. Interesting volume and movement recently. Sure appears that something is happening

Expecting a run before pull back, expecting some India news, that is what I am betting on,
This is one of my hype stocks, one where people are waiting for some news for it to move, with no real revenues they rely on the hype, hope, sizzle. They have possibilities so this may be fun

i dont think dennis or anyone else would start selling until after news, even though too many shares are out there many sales have occurred in past yr so a lower average price may give holders some time

I also think the risk is low at this level

I thought this was a QB stock, it’s showing as QX on OTC Markets. Is that new or am I trippin’

https://www.otcmarkets.com/stock/MVMDF/disclosure

New monthly filed for Canadian counterpart, not much changed from last month.

https://webfiles.thecse.com/2022-01-05_-_MVMDH_-_Form_7_-_December_2021_Monthly_Progress_Report_-_FINAL.pdf?jk3TR.aPdxZA5VGh8JdsUpi8Hqvu2bxI

Yes, have order in for the open to add to my position, news could be variety of things but I am betting that India finally approved something.
I will evaluate if I hold longer after seeing the news,
I dont like buying at the open however I am feeling lucky today, playing craps and rolling a seven

Gotta say something’s brewing, big money loading up here on the back end these last couple days here or just big shorts closing. Couldn’t find anything in fillings/news anywhere. Added today just in case.

Lol. Your comment doesn't mean much when your whole post history is calling everything a scam. Good luck to you, I think maybe 3 people actually read this stock's board. Nice day here though, wonder what's up?

MVMDF, Scam, a dead cat bouncing, then Crashing.

Well more about the Canadian stock standing, no fins or info on the American version.

You can get an idea from the last Form 7.

https://webfiles.thecse.com/2021-12-05_-_MVMDH_-_Form_7_-_November_2021_Monthly_Progress_Report_-_FINAL.pdf?dbtBx8IDc_9wDHbKqFNdRDPSe0VO7FWQ

Where are their finances? Anyone know how much money they have?

This thing tanked from $2 > .08 what a POS.

India has done well with ivermectin

This may start waking up, better volume today with a tick up
Shareholder Update had lots of clues on positive developments, maybe he cannot confirm some items however they are moving forward with two main items.
1 Moving forward with more trials on cancer, so to me that means they dont have any negative issues to hold back further work. I view this as positive.
2 moving forward on setting up supply for India as he basically says they expect India Health approval. probably does not have anything official but said the testing/trials are finished so he knows the results and says they will commercialize in India, I view that as positive.

I think we will see a reversal here and expect more news that will support this price level.
Will have to hope He has cash to fund actions and does not dilute this stock until later, after all the confirming news

Indiamectin

Read about the news blackout on ivermectin and India

We are deceived

gonna run soon

nice ss

Watchin the Ivermectin train picking up more passengers.

Dr. Ozaki, The chairman of the Tokyo Metropolitan Medical Association, recently led an emergency press conference on August 13, Dr. Haruo Ozaki to say they will use ivermectin to help with their increase in covid positive people because he has seen in other countries that it helps.

As More issues with mass vax come out, the voice for early treatment is getting stronger. Look for Florida to Not threaten anyone for Ivermectin.

MV needs to work harder to make some noise, needs the PR & results he has been promising from India so that the selling slows down and potentially waits until this price is higher.

https://www.otcmarkets.com/stock/MVMDF/news/Mountain-Valley-MD-Announces-Appointment-of-Advisors-Stock-Option-Grant-and-Provides-Uplisting-Update?id=311786

https://www.forbes.com/sites/nealtaparia/2021/07/14/this-entrepreneur-is-on-a-mission-to-tackle-global-health-challenges/?sh=76aec7042f30

Transparency lads
Who owns the stock?
All 330,000 000 shares..
What did they pay for it?

How much money does the company have?

How much co stock did you sell
When proce was over $1?

Are there warrants out?
Options out?

Where is the endless supply of sellei
G stock coming from????

Seems I should just wait for a nickel here to buy again.

Teens then subteens.

Nice news.

https://assets-global.website-files.com/60085ac8fa8263a049a4d1b4/60d481abf92d11605475d381_PR%202021-06-24%20-%20MVMD%20Corporate%20Update.pdf

https://webfiles.thecse.com/2021-06-05_-_MVMDH_-_Form_7_-_May_2021_Monthly_Progress_Report_-_FINAL.pdf?iLxoZa_eVkYjnMlVyMww1mPV_9a44Co6

Nice move here today. Once the crooked government lab rats get out of the way this companies tech and stock is gonna rip! IMHO. GLTA

The institutional selling is amazing considering they will have positive news in next 30-60 days. Debt or past unit buyers/holders must want to cash out bad. Lots of big selling to drag this down and not sure when it will stop.

I will wait until selling is finished to buy more.
My opinion is Ivermectin has been proven to work in variety of countries for covid, India is using Ivermectin in some form now and its working. I think their India trials will work so Question becomes how well positioned is MVMD to capitalize on and become a preferred use drug in India or anywhere else?
I hope their India partners are good and connected.
Welcome any knowledge/input on these questions

I thought by now this would at least be channeling. I like their research, pricing sucks currently though.

NYT Article “I Don’t Know of a Bigger Story in the World” Right Now Than Ivermectin: NY Times Best-Selling Author
Posted on May 25, 2021 by Nick Corbishley

The technology looks fine, maybe its generic but it does have a purpose so they have a sales pitch and a base to start generating revenue.

The Ivermectin train is going to carry a variety of companies higher as more and more information gets to public. Also when the media and medical bureaucrats stop shutting down all the positive effects this drug will make a big comeback in the US. (Already doing well around world)

McM I agree mgmt put too many shares out there and as we saw over the recent past the stock sales are tremendous. I try to watch the canadian exchange volume/trades and they have been selling big. I have a couple buy ins now as I am looking for the turn.
Today was actually a better buy volume.

As mentioned before I think this will be a good momentum play with Ivermectin leading the publicity. I will be in this for a month or two for the gains then I will be out.
I Never fall in love with a stock/company. That was my past trading life, now I am interested in companies like this that have a hook and news to move it higher.

I would look at the changes algernon
Has done to respect the market place..

That is a decent risk reward..

I would like to see ownership go into the Capital structure and justify the number of shares outstanding , who owns them and what they have invested to deserve them..

And who is on the Board of Directors to protect other shareholders..

Smitty
At $.10 this still has a 36,000,000 valuation..
Patents?
I have not done due dilligence on patents..
Have you?

When the insiders add shares in the open market.. I am a buyer..

Show us the greed insiders
..show when YOU think your stock is worth owning..

News will carry this one for the next two months. I understand what you are saying and agree if this was a typical manufacturing company with no ability to have a break through event. Logic would not buy this, I would not look at this one and would agree they are releasing shares, as well as the block trading appears to be non retail. Since I have bot in I have been looking at the canadian exchange trading instead of this OTC version. I thought I was buying in near the bottom of the selling, so I find I am buying more at the lower price.

My confidence is high this will turn up with news instead of fundamentals.

For me this is a short term play, 2-3 months, to see how much the good news will carry this one. I think this is an easy double from here. Lots of covid/medical stock have had big runs. This one is starting to catch some press. Then we will see if the ceo can run a company and justify the value.

MVMD triggered a breakout alert. Eyes on. Catalysts will send this flying to previous highs. GLTA

Smitty.. they can’t throw around these shares.. they are issued and outstanding.
Somebody owns them.. Who?

Why? What did they pay for them?

Let me know please..

Because I feel like so many Canadian investments.. and others too..
They set up Capital steucture so almost impossible for other outside investors to profit..

I think they ha e a billion plus product..

But.. how many more shares will they “issue” to friends amd family? And the options? Free Markets are a trust game..

I don’t have hours to review the Capital structure and how 300,000,000 shares are out.. and it appears that they don’t have much more than two employees..
And how much $$$ do they have in bank?

Do they have debt?

They need to tighten up their Capital structure.. build confidence in investment community that short sellers can’t attack Ad nauseum,

I hate reverse splits.. but .. this appears to be ripe for one.. 15 to 1... upgrade your trade to TSX than Nasdaq..and hammer home the opportunity in Bangladesh..


Save lives..


Otherwise .. it’s always going to be what it is now..
Pump and dump
The n
Short and distort

I am patiently waiting for another buy signal as the trading on the canadian stock has alot of medium sized block sales which can mean either someone has stock to unload or they want this price brought down.
Not sure but I have seen when known news is coming they will bring stock down to load up, this feels like that because the news coming from India should be good and move this price higher.
I will wait until they are done and then buy again. Watching volume & qty share trades past couple days

That is a lot of stock in market place to trade 50,000 shares a day..
This really was great news today..
Insanely disappointing that the people who have the most to gain.. don’t buy more on this news..

Makes a guy go.. why don’t my dogs bark when you comes ‘round ky door..
My dogs bark at everyone..